Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Adam Dubow Sells 4,319 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Adam Dubow sold 4,319 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $38,482.29. Following the sale, the insider owned 62,626 shares in the company, valued at approximately $557,997.66. The trade was a 6.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Day One Biopharmaceuticals Stock Down 3.1%

DAWN traded down $0.27 during trading on Tuesday, hitting $8.57. The company’s stock had a trading volume of 1,531,756 shares, compared to its average volume of 1,496,830. The firm has a market capitalization of $879.97 million, a P/E ratio of -5.64 and a beta of -1.25. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.64 and a twelve month high of $14.46. The stock’s fifty day moving average price is $7.63 and its 200-day moving average price is $7.05.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.09. The company had revenue of $39.80 million during the quarter, compared to analyst estimates of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. Day One Biopharmaceuticals’s revenue for the quarter was down 57.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.38 EPS. Equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DAWN shares. Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. Needham & Company LLC dropped their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Piper Sandler raised their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $24.43.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. PharVision Advisers LLC purchased a new stake in shares of Day One Biopharmaceuticals during the third quarter valued at approximately $299,000. XTX Topco Ltd grew its stake in Day One Biopharmaceuticals by 224.9% in the 3rd quarter. XTX Topco Ltd now owns 78,848 shares of the company’s stock valued at $556,000 after purchasing an additional 54,580 shares during the period. Polymer Capital Management US LLC bought a new position in Day One Biopharmaceuticals in the 3rd quarter valued at $134,000. Quarry LP purchased a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at $49,000. Finally, Qube Research & Technologies Ltd raised its stake in shares of Day One Biopharmaceuticals by 23.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,167,669 shares of the company’s stock worth $8,232,000 after purchasing an additional 223,467 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.